Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Time to Buy?Market Beat·1 day ago, 12:00 PMURGN-1.80%
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?Simplywall·2 days ago, 06:33 PMURGN-1.80%
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - What's Next?Market Beat·Aug 6 at 05:00 AMURGN-1.80%
Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New Highrttnews·Aug 5 at 10:40 PMPRGO+1.10%BJDX+0.95%
Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPSMarket Beat·Aug 5 at 01:56 PMURGN-1.80%
URGN: Q2 revenue soared on ZUSDURI growth, with robust pipeline and profitability outlook maintainedQuartr·Aug 5 at 11:00 AMURGN-1.80%
URGN: Q2 2026 revenue jumped to $72.5M, net loss narrowed, and cash reserves remain strongQuartr·Aug 5 at 08:16 AMURGN-1.80%
Urogen Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 72.46 MEarnings Watch·Aug 5 at 07:04 AMURGN-1.80%
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and HighlightsUnusual Whales·Aug 5 at 07:03 AMURGN-1.80%
UroGen Q2 FY26 net loss narrows to $14.4 million; revenue rises to $72.5 millionPUBT·Aug 5 at 07:02 AMURGN-1.80%
Swiss National Bank Makes New $1.40 Million Investment in Urogen Pharma $URGNMarket Beat·Aug 1 at 04:12 AMURGN-1.80%MS+0.34%
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·Jul 29 at 01:14 AMURGN-1.80%
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy RatingTip Ranks·Jul 21 at 01:58 PMURGN-1.80%
